AI Summary

A new study from the University of Kentucky Markey Cancer Center shows that melanoma not only resists MAPK inhibitors but also actively suppresses immune cells. Researchers published the findings in Nature Communications and identified the proteins ABL1 and ABL2 as key drivers of both drug resistance and immune evasion. These proteins normally regulate cell growth, survival, and communication, but when overactive they keep melanoma cells proliferating despite treatment. They also trigger signals that recruit immune‑suppressing cells while preventing cancer‑fighting T cells from attacking the tumor.

AI summaries can be wrong sometimes—always verify important details using the source article.